Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis

Exclusion Criteria

• •1. Fixed inguinal lymph nodes (cN3),
• •2. Iliac lymph nodes (cN3),
• •3. Patients pN3,
• •4. prior chemotherapy for squamous cell carcinoma of the penis,
• •5. Against-indication for chemotherapy or known hypersensitivity to cisplatin, ifosfamide or paclitaxel,
• •6. Patients treated with phenytoin,
• •7. Patients with hearing loss \>Grade 1 (CTCAE V4.03),
• •8. Patients with cardiopulmonary disease-indicating against overhydration,
• •9. History of cancer within 5 years prior to inclusion in the trial other than cutaneous basal cell,
• •10. Patient received a live attenuated vaccine within 30 days prior to inclusion,
• •11. Patients already included in another clinical trial or receiving an experimental treatment within 30 days prior to inclusion in the trial,
• •12. Patients deprived of their liberty or under court protection including guardianship,
• •13. Severe systemic disease or uncontrolled or any other chronic or acute illness that is incompatible with the patient's participation in the trial according to investigator,
• •14. immunocompromised patients including with known seropositivity (HIV),
• •15. Patients with mental impairment which prevents the understanding of the protocol or having a psychological state, family, sociological or geographical conditions that would not allow compliance with the protocol and the planned follow-up or any condition which, according to the investigator, would prevent participation patient tested. These conditions should be assessed before inclusion of patients.